Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo.

Stephen Britland; Annie Smith; Wayne Finter; Donald Eagland; Kath Vowden; Peter Vowden; Gary Telford; Alan Brown; David Pritchard

doi:10.1002/btpr.587

Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo.

Identifier:nobleid.org/w1/20260515/C01C1E5C

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C01C1E5C.svg?ark=w1%2F20260515%2FC01C1E5C)](https://nobleid.org/work/w1/20260515/C01C1E5C)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo.

Identifier:nobleid.org/w1/20260515/C01C1E5C

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C01C1E5C.svg?ark=w1%2F20260515%2FC01C1E5C)](https://nobleid.org/work/w1/20260515/C01C1E5C)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work